) — formerly known as GlaxoSmithKline — are sliding in pre-market trading and into Monday's session open following a court ruling that has approved more than 70,000 lawsuits to go forward over heartburn medication Zantac's alleged links to cancer.Shares of GSK they're plunging after a court ruling, stating the drug maker must face trials over claims that its heartburn medication, Zantac causes cancer.
But obviously, when you see a move to this extent here, like we're seeing today, there are some concerns at least short term, what exactly this is going to mean for a Glass E Smith client's business.Yeah, GSK expected to appeal and also they uh had put out a statement saying that the studies, oh, got that one.
Cathie Wood's ARK Invest missed out on more than $1 billion in returns by selling Nvidia stock too early America’s gummed-up housing market is a $45 trillion mess — a big old knot of economic forces smashing into a century’s worth of cultural conditioning about the value of homeownership.Missed NVIDIA? Check Out This Semiconductor AI Penny Stock
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BNNBloomberg - 🏆 83. / 50 Read more »